Compare MasTec Inc (MTZ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Recursion Pharmaceuticals Inc — how do they compare? MasTec Inc trades at $240.8 (market cap $19.77B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: MasTec Inc is far larger — about 10.6× Recursion Pharmaceuticals Inc's market cap, and MasTec Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| MTZ | RXRX | |
|---|---|---|
Market Cap | $19.77B | $1.86B |
Sector | Technology | Health |
52-Week High | $437.51 | $6.79 |
52-Week Low | $189.18 | $2.84 |
Enterprise Value | $22.69B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $246.18, up 3.79% today, with strong analyst support (88.9% buy ratings) and a consensus price target of $436.50. The stock shows bearish technical signals but benefits from record $21.4B backlog and AI infrastructure exposure. Recent Q2 2026 earnings missed expectations slightly, though revenue grew 23% year-over-year. The company raised its 2026 outlook, highlighting expanding data center capabilities and power delivery growth.
MTZ presents a growth opportunity driven by infrastructure demand and AI-linked projects, but faces risks from premium valuation (P/E 39.2), weak cash flow trends, and communications segment softness. Investors should weigh strong institutional interest against execution challenges in a competitive market.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
